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INTRODUCTION
Oxygen is essentially required by the aerobic metabolisms
of most eukaryotic organisms. It functions as an electron sink
to be reduced by four electrons and produce water in the final
step of oxidative phosphorylation. Thus organisms and cells
have developed numerous adaptive mechanisms that enable
them to survive in oxygen-depleted conditions. At the organ-
ism level, hypoxic adaptation includes reflex hyperventila-
tion, increased production of red blood cells, and new vessel
formation, which in combination lead to increased oxygen
delivery from the atmosphere to the tissues (1). At the cellu-
lar level, the adaptation involves a switch of energy meta-
bolism from oxidative phosphorylation to anaerobic glyco-
lysis, increased glucose uptake, and the expression of stress
proteins related to cell survival or death (1, 2). The regula-
tion of most proteins required for hypoxic adaptation occurs
at the gene level, which involves transcriptional induction
via the binding of a transcription factor, hypoxia-inducible
factor-1 (HIF-1), to the hypoxia response element (HRE) on
the regulated genes (2, 3) (Fig. 1). 
This review aims to summarize our current knowledge of
the regulation of HIF-1.
DISCOVERY OF HIF-1
Before HIF-1 was found, HRE had been identified in the
3′ -enhancer region of the erythropoietin gene, whose tran-
scription is up-regulated by more than 100-fold by severe
hypoxia (4-6). Semenza and Wang (7) defined a binding site
critical for the hypoxia-inducible function, which involves a
transcription factor induced by hypoxia. Subsequently, they
purified a DNA-binding complex bound to the HRE by
affinity-purification using oligonucleotide with the HRE
sequence (8), and thus identified the encoding cDNAs (9).
HIF-1 was found to be a heterodimer composed of two basic-
helix-loop-helix (bHLH) proteins of the PAS family, HIF-1
and HIF-1 . Of these, HIF-1 had previously been identified
as the aryl hydrocarbon nuclear receptor translocator (ARNT),
which is dimerized with the aryl hydrocarbon receptor. How-
ever, HIF-1 was a newly defined protein and uniquely asso-
ciated with the transcription of the hypoxia-inducible genes.
Later, homology searches in the gene bank and cloning experi-
ments found other members of this family, such as HIF-2
(also known as endothelial PAS protein-1) (10, 11) and HIF-
3 (12). HIF-2 is also tightly regulated by oxygen tension
and its complex with HIF-1 appears to be directly involved
in hypoxic gene regulation, as is HIF-1 (13). However, al-
though HIF-3 is homologous to HIF-1 , it might be a nega-
tive regulator of hypoxia-inducible gene expression (14). 
STRUCTURE OF HIF-1
HIF-1 is an 826-amino acid protein, as shown in Fig. 2.
Its N-terminal half contains the basic domain (aa. 17-30), a
helix-loop-helix domain (aa. 31-71), and a PAS domain (aa.
85-298), which are required for dimerization with HIF-1
and binding to the HRE DNA core recognition sequence
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Oxygen-Dependent and -Independent Regulation of HIF-1alpha
Hypoxia-inducible factor-1 (HIF-1) is composed of HIF-1alpha and HIF-1beta, and
is a master regulator of oxygen homeostasis, playing critical roles in physiological
and pathological processes. Normally, the formation and transcriptional activity of
HIF-1 depend on the amount of HIF-1alpha, and the expression of HIF-1alpha is
tightly controlled by the cellular oxygen tension. Recent progress in the study of
its regulation mechanism provided clues as to how HIF-1alpha is regulated by
oxygen. It appears that HIF-1alpha is not regulated only by the oxygen tension,
but also by various other stimuli, such as transition metals, nitric oxide, reactive
oxygen species, growth factors, and mechanical stresses. In this review, we sum-
marize the oxygen-dependent and -independent regulation of HIF-1alpha, and
the respective physiological and pathological meanings. 
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(5′ -RCGTG-3′ ). The PAS domain is divided into two sub-
domains, PAS-A (aa. 85-158) and PAS-B (aa. 228-298) (9).
The C-terminal half of HIF-1 is required for transactivation.
The transactivation domains (TADs) are localized to aa. 531-
575 (N-terminal TAD) and aa. 786-826 (C-terminal TAD),
which are separated by an inhibitory domain (15, 16). Nuclear
localization signals (NLSs) are localized at N-terminal (aa.
17-74) and C-terminal (aa. 718-721) of HIF-1 (17). The C-
terminal NLS motif plays a critical role in mediating hypoxia-
inducible nuclear import of HIF-1 , whereas the N-terminal
one may be less important. Moreover, the C-terminal half
contains two PEST-like motifs at aa. 499-518 and 581-600
(9). The PEST motif contains a sequence rich in proline (P),
glutamic acid (E), serine (S), and threonine (T). Since this
motif has been found in many proteins with half-lives of less
than 2 hr, proteins containing the PEST motif tend to be
targets for rapid intracellular degradation. HIF-1 is also a
very unstable protein with a short half-life less than 10 min
under normoxic conditions. Salceda and Caro (18) first re-
vealed that HIF-1 is ubiquitinized under normoxic condi-
tions, and then targeted by proteasome. Later, Huang et al.
(19) clearly defined the domain responsible for the normoxic
destruction of HIF-1 , and designated it the oxygen-depen-
dent degradation domain (ODDD). The ODDD (aa. 401-
603) contains PEST-like motifs, and controls HIF-1 degra-
dation by the ubiquitin-proteasome pathway. 
OXYGEN-DEPENDENT REGULATION OF HIF-1
How does the ODDD regulate the ubiquitination of HIF-
1 , in an oxygen tension dependent manner? Recently, sev-
eral leading research groups shed light upon the answer to
this question. The mechanisms of oxygen sensing and HIF-
1 regulation are summarized in Fig. 3. Maxwell et al. (20)
first demonstrated that the von Hippel-Lindau tumor sup-
pressor protein (pVHL) binds directly to HIF-1 oxygen-
dependently, and that this leads to the proteolysis of HIF-1 .
Later, the role of pVHL in this process was clearly elucidated
by biochemical and structural studies. pVHL participates in
the ubiquitination of HIF-1 as a part of an E3 ubiquitin lig-
ase protein complex (21, 22), in which the beta-domain of
pVHL interacts directly with the ODDD of HIF-1 (23).
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Fig. 1. Identified HIF-1 target genes. Abbreviations: , HIF-1 ;  , HIF-1 ; HRE, hypoxia response cis-element.
Fig. 2. Structure of the HIF-1 gene and protein. The HIF-1 gene
is composed of 15 exons and 14 introns. The protein possesses
basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domain,
which are involved in DNA binding and dimerization with HIF-1 .
Its C-terminal part contains two transacting domains (TAD), an
inhibitor domain (ID), and a nuclear localization signal (NLS). The
oxygen-dependent degradation domain (ODDD) contains two
subdomains targeted by the von Hippel-Lindau protein (pVHL)
at its N-terminal and C-terminal ends.
Structure of 
the HIF-1 gene
Structure of 
the HIF-1 proteinpVHL associates with the peptides containing the ODDD
extracted from cells cultured under normoxic conditions, but
does not associate with the peptides from cells cultured under
hypoxic conditions. However, another important question
remains still. What determines the oxygen-dependent inter-
action between HIF-1 and pVHL? Recent insight comes
from the demonstration that the pVHL-dependent ubiqui-
tination of the N-terminal (aa. 390-417) (24) or the C-termi-
nal part (aa. 549-582) (25, 26) within the ODDD is preceded
by the hydroxylation of a proline residue (HIF-1 402 and
564), present in each part. These proline residues are embed-
ded within the amino acid motif LXXLAP, which is con-
served in the HIF-1 proteins of other species and HIF-2 .
Recently, three isoforms of HIF-1-prolyl hydroxylase (PHD1-
3) were found to be able to hydroxylate the motif targeted by
pVHL (27, 28). Sequence analyses imply that these PHD
enzymes belong to a subfamily distinct from the procollagen
prolyl hydroxylases, which hydroxylate proline residues in
procollagen and stabilizes collagen. These enzymes use molecu-
lar oxygen as a substrate and ferrous ion as a cofactor, and
generate carbon dioxide and succinate as by-products (29).
Since the activities of these enzymes depend on the concen-
trations of oxygen and iron, depletion of these molecules
might limit the hydroxylation of proline residues in HIF-1 ,
thereby precluding binding of pVHL to HIF-1 and stabiliz-
ing HIF-1 . Thus it presents a good scenario for explaining
how HIF-1 is regulated by the level of oxygen or iron. 
OXYGEN-INDEPENDENT REGULATION OF HIF-1
Transition Metals 
Transition metal ions, such as cobalt and nickel, stabilize
HIF-1 under normoxic conditions, and induce HIF-1 activi-
ty and the expression of its downstream hypoxia-inducible
genes (13, 30). Previously, cobalt and nickel ions were sug-
gested to substitute for the iron atom in the heme moiety of
the putative oxygen sensor protein, thereby locking the pro-
tein in its deoxygenated state (31). The presence of the puta-
tive oxygen sensor is also supported by experiments showing
that carbon monoxide, on binding to heme, suppresses both
the hypoxic accumulation of HIF-1 and erythropoietin pro-
duction (32). Cobalt and nickel ions have been shown to be
substrates for ferrochelatase, an enzyme responsible for the
incorporation of iron into protoporphyrin IX, and are incor-
porated into heme (33). Cobalt or nickel protoporphyrin IX
binds oxygen with a lower affinity than iron protoporphyrin
IX (34) and in turn this poorer binding may mimic low oxy-
gen tension, which results in HIF-1 activation. Besides these
metal ions, zinc ion also can replace heme iron, and the result-
ing zinc protoporphyrin IX has a similarly low affinity to
oxygen (35). A recent report demonstrated that zinc stabi-
lizes HIF-1 under normoxic conditions, further supporting
this hypothesis (36). However, other hypothesis about the
metal ion-mediated induction of HIF-1 could be suggested
from recent reports (27, 29). As mentioned in the previous
section, PHD can participate in the HIF-1 stabilization by
metal ions. Ferrous ion, a cofactor of PHD, is coordinated by
two histidine residues and a carboxylated residue in PDH.
If this metal binding is not tight, however, other metal ions
could substitute for the ferrous ion bound to PDH, and inhib-
it its enzymatic action, which might stabilize HIF-1 even
under normoxic conditions. 
Nitric Oxide 
Hypoxia stimulates nitric oxide (NO) production through
the induction of inducible NOS, the transcription of which
is enhanced by HIF-1 (37, 38). Conversely, NO affects the
HIF-1-mediated induction of the hypoxia-inducible genes,
such as the erythropoietin and vascular endothelial growth
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Fig. 3. Oxygen-dependent regulation of HIF-1 .
Under normoxic conditions, HIF-1-prolyl hydrox-
ylases (PHD) hydroxylate the prolyl residues at
amino acid 402 and 564. These enzymes require
dioxygen, Fe
2+, ascorbate, and 2-oxoglutarate
for activity. The hydroxylated peptides interact
with an E3 ubiquitin-protein ligase complex com-
posed of VHL, elongin B&C, and Cullin 2 (CUL2),
and then poly-ubiquitinized, resulting in HIF-1
degradation by the 26S proteasome. Under hy-
poxic conditions, HIF-1 is not hydroxylated
because the major substrate, dioxygen, is not
available. The unmodified protein escapes the
VHL-binding, ubiquitination, and degradation,
and then dimerizes HIF-1 and stimulates the
transcription of its target genes.584 Y.-S. Chun, M.-S. Kim, J.-W. Park
factor genes. However, the effect of NO on HIF-1 expression
is reciprocal, and may depend on the chemical structure and
the concentration of the NO donor used. The effect of NO
on HIF-1 is attributed to two research groups. They showed
that NO at relatively high concentrations reduces the hypoxic
induction of HIF-1-DNA binding and the transcriptional
activity of HIF-1 (39, 40). Subsequently, Huang et al. (32)
revealed that NO not only blocks the hypoxic stabilization
of HIF-1 but also represses its transcriptional activity. Car-
bon monoxide, which has a well-known ability to block the
induction of the hypoxia-inducible genes, showed similar
effects on HIF-1. Based on this effect of NO, Chun et al. (41)
found a new inhibitor of HIF-1 , YC-1, which also suppresses
HIF-1 activity and the hypoxic induction of the erythropoi-
etin and vascular endothelial growth factor genes. In addition,
NO and YC-1 effects were suggested to be linked with a
metal-related oxygen sensing pathway, and not with soluble
guanylate cyclase stimulation. However, it was demonstrat-
ed later that NO under different conditions can induce the
accumulation of HIF-1 even under normoxic conditions
(42, 43). Why does NO show these reciprocal effects on HIF-
1 , inhibition and stimulation? This question remains unan-
swered thus far. In our opinions, the direction of the NO effect
may be determined by the concentration of NO itself. Accord-
ing to experiments demonstrating the inhibitory effects of
NO, 100 M sodium nitroprusside (SNP) and 3 mM S-nit-
rosoglutathione (GSNO) were used to generate NO. Since
SNP releases NO quickly, 100  M of SNP can produce a
higher concentration of NO. We believe that NO was pre-
sent at high concentrations under these experimental condi-
tions. However, in experiments that demonstrated the stim-
ulatory effects of NO, GSNO or other donors were used at
the concentration of 100-200  M. In terms of GSNO, the
concentrations used for HIF-1 activation were 5 to 10-fold
lower than that used for HIF-1 suppression. Moreover, Kimu-
ra et al. (44) showed that S-nitroso-N-acetylpenicillamine
(SNAP), another NO donor, stimulates HIF-1 activity under
normoxic conditions at concentrations of less than 0.5 mM,
but that it inhibits HIF-1 activity under both hypoxic and
normoxic conditions at concentrations of more than 0.5 mM.
Therefore, we suggest that the effect of NO on HIF-1 depends
upon its concentration. 
Reactive Oxygen Species
In general, it is believed that reduced environmental oxy-
gen tension causes a decrease in the cellular levels of reactive
oxygen species (ROS), which leads to the stabilization of HIF-
1 and the activation of HIF-1. Wang et al. (45) demonstrat-
ed that strong oxidizing reagents impair the expression of
HIF-1 in hypoxic cells and the DNA-binding activity of
HIF-1. Evidence of this redox-dependent regulation of HIF-
1 has been provided by several experiments (46, 47). Recently,
however, another hypothesis on the ROS production under
hypoxic conditions has been introduced. The respiratory chain
in mitochondria is one of the major ROS generation sites.
Many reagents, which block the electron flow in this respira-
tory chain, cause an accumulation of electrons in the respira-
tory compartments prior to the compartment being blocked
by an inhibitor, and then produce ROS because molecular
oxygen can be reduced univalently by electrons leaking from
the fully reduced compartments (48). In cases of oxygen defi-
ciency, similarly, the last step in the respiratory chain is block-
ed because oxygen is essentially required for removing elec-
trons. Electrons thus accumulate in the respiratory chain and
produce ROS by reducing oxygen remaining in the mito-
chondria (49). Therefore, ROS production by mitochondria
increases under hypoxic conditions, although the total level
of intracellular ROS might be reduced because of a decrease
in the ROS production by other oxidases. Based on this hy-
poxic increase in ROS generation from mitochondria, Chan-
del et al. (50) suggested that the mitochondrion acts as an
oxygen sensor by increasing ROS production during hypoxia.
They demonstrated that there is a positive relationship be-
tween ROS production and HIF-1 activation, and that mito-
chondria are essential for HIF-1 activation, by using Hep3B
cells depleted of the mitochondria. Subsequently, this research
group reported that ROS generated by the mitochondrial
complex III participates in HIF-1 stabilization (51). In addi-
tion, it has been demonstrated that HIF-1 is up-regulated
even under normoxic conditions by cytokines generating ROS
(52, 53). Taken together, it is hard to draw a simple conclu-
sion on the effect of ROS on HIF-1 . ROS seems to regulate
the stability of HIF-1 in the opposite direction. The direc-
tion of ROS effect may be determined by the production
amount and subcellular distribution of ROS.
Growth Factors
A growing body of evidence indicates that HIF-1 contri-
butes to tumor progression and metastasis (54, 55). Immuno-
histochemical analyses show that HIF-1 is present at high
levels in human tumors. Moreover, the expression levels of
HIF-1 in the biopsies of various solid tumors correlate with
tumor aggressiveness, vascularity, treatment failure, and mor-
tality. In addition, tumor growth and angiogenesis in grafted
tumors also depend on the HIF-1 activity or the expression
level of HIF-1 . During tumor development, HIF-1 induces
the expression of the gene products that promote angiogen-
esis, such as vascular endothelial growth factor, basic fibrob-
last growth factor, angiopoietin 2, and adrenomedullin (56).
In addition, it aids tumor cell survival under hypoxic condi-
tions via the expression of gene products that promote anaer-
obic ATP synthesis, such as glucose transporters (1, 3), a series
of glycolytic enzymes (aldolase A and C, enolase 1, hexoki-
nase 1 and 3, lactate dehydrogenase A, phosphofructokinase
L, and phosphoglycerate kinase 1), and cell survival factors
(insulin-like growth factor 2 and insulin-like growth factorRegulation of HIF-1 protein 585
binding proteins) (57). In solid tumors, intratumoral hypoxia
and genetic alterations that affect the expression of the VHL
tumor suppressor gene are undoubtedly important mechani-
sms of the over-expression of HIF-1 . In addition, the growth
factor-mediated activation of phosphatidylinositol-3-kinase
(PI3K) contributes to the expression of HIF-1 in tumors.
The growth factor-dependent expression of HIF-1 was first
demonstrated in prostate cancer cells, in which HIF-1 is con-
stitutively expressed even under normoxic conditions (58).
Growth factors reported to elicit such effect, include insulin
(59), insulin-like growth factor (59, 60), epidermal growth
factor (61), and interleukin-1 (62). These growth factors are
known to stimulate their receptors and activate the receptor
tyrosine kinases, and in turn sequentially activate PI3K, a
serine/threonine kinase AKT (also known as protein kinase
B), and FKBP-rapamycin associated protein (FRAP). Finally,
the FRAP stimulates the expression of HIF-1 under nor-
moxic conditions (61) (Fig. 4). On the other hand, this path-
way is negatively regulated by the PTEN tumor suppressor
protein, which dephosphorylates the products of the PI3K
(63). Therefore, the activation of the PI3K pathway and ge-
netic alterations to affect the expression of PTEN are consid-
ered to be important mechanisms responsible for the normox-
ic expression of HIF-1 in tumor cells. Similarly, the increased
activity of human epidermal growth factor receptor 2 (HER2,
also known as neu) contributes to the over-expression of HIF-
1 in breast cancer cells (64). HER2 has tyrosine kinase activi-
ty in the absence of any known ligand, and is known to stim-
ulate the PI3K/AKT/FRAP pathway. Since genetic alterations
that increase the HER2 activity occur in approximately one-
third of breast tumors and are associated with increased tumor
grade (65), the HER2-mediated induction of HIF-1 is con-
sidered to be an important mechanism for the development
of breast tumors. Interestingly, Laughner et al. (64) also found
that the HER2-mediated induction of HIF-1 is promoted
by a novel mechanism. As described previously, the level of
HIF-1 is regulated by a post-translational modification of
prolyl hydroxylation. However, the HER2/PI3K/AKT/FRAP
pathway regulates the level of HIF-1 at the translational
level, and enhances the rate of HIF-1 protein synthesis from
its mRNA. In this process, the 5′ -untranslated region of HIF-
1 mRNA may be targeted by the pathway (64). However,
it is not clear whether this new mechanism occurs in other
cells and under other experimental conditions.
Mechanical Stress
Although HIF-1 is not usually detected in cancer cells
cultured under normoxic conditions, HIF-1 is detected im-
munohistochemically in the nuclei of normal mouse tissues,
such as brain, kidney, liver, and heart, and increased in re-
sponse to whole body hypoxia (66). The existence of HIF-1
in normoxic tissues suggests that HIF-1 may be required
for maintaining the basal expression of the essential genes
regulated by HIF-1. Moreover, the accumulation and nucle-
ar targeting of HIF-1 has been observed in ischemic tissues
(67). Although the pathophysiology of ischemia is more com-
plicated than that of hypoxia, reduced oxygen tension in is-
chemic tissues might be the major causative factor behind
the stimulation of HIF-1 induction. Clinically, HIF-1 induc-
tion in the heart has great significance, as HIF-1 has been
observed to be induced in the ischemic human myocardium.
In biopsy specimens obtained from ischemic or infarcted
myocardium, HIF-1 and VEGF proteins were detected by
immunohistochemical staining (68). These results suggest
that the early induction of HIF-1 mediates the transcription
of the VEGF gene in the ischemic myocardium, which is one
of the first adaptations of the human myocardium to ischemia.
In the rat heart myocardial infarction model, however, VEGF
expression was found to be induced in the normoxic myocar-
dium remote from the infarct area (69). This suggests that
stimuli other than ischemia might be responsible for the
VEGF induction. Recently, Kim et al. (70) demonstrated
that HIF-1 accumulated in the nuclei of cardiac myocytes
in the non-ischemic myocardium, and found that this was
followed by the induction of the VEGF gene in the same site.
Fig. 4. Signal transduction pathways promoting non-hypoxic ex-
pression of HIF-1 . Even under normoxic conditions, HIF-1 can
be induced by growth factors and mechanical stresses. The
oxygen-independent regulation of HIF-1 is commonly mediated
by the PI3K-AKT-FRAP pathway. The involvement of this path-
way has been examined using specific inhibitors denoted at
the right side. 
Abbreviations: IGFR, insulin-like growth factor receptor; EGFR,
epidermal growth factor receptor; IL-1, interleukin-1; HER2, human
epidermal growth factor receptor 2; SACs, stretch-activated
channels; PI3K, phosphatidylinositol-3-kinase; AKT, protein kinase
B; FRAP, FKBP-rapamycin-associated protein; PTEN, phospha-
tase and tensin homolog deleted on chromosome 10.
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They also found that wall stretch causes HIF-1 induction
in the non-ischemic myocardium. Interestingly, the PI3K/
AKT/FRAP pathway, which is activated during the early
phase of wall stretch, stabilizes HIF-1 protein in the heart,
as the pathway involves the HIF-1 induction in prostate can-
cer cells. Moreover, the stretch-mediated induction of HIF-
1 and VEGF was suppressed by gadolinium (a stretch-acti-
vated channel inhibitor) (Fig. 4). These results imply that
HIF-1 plays important roles not only in the adaptation to
ischemia but also in the adaptation to mechanical stress. A
similar in vivo finding was obtained in vascular smooth mus-
cle of the aorta subjected to hypertension (71). In this case,
after being subjected to hypertension for three days, cells posi-
tively stained with anti-HIF-1 and anti-VEGF antibodies
appeared and increased further over seven days. As increased
blood pressure causes the wall of the aorta to stretch, the asso-
ciated mechanical stress may cause the induction of HIF-1
in the muscle cells of the aorta. Taken together, the mechani-
cal stress-mediated, non-hypoxic induction of HIF-1 seems
to be a common phenomenon, which occurs in the muscular
tissues that compose the cardiovascular system. However, it
is not clear how the muscle cells sense mechanical stress and
signal the PI3K - HIF-1 pathway. 
CONCLUSION
HIF-1 is a master regulator of oxygen homeostasis, and
plays critical roles in physiological and pathological processes.
To date, approximately four dozen genes targeted by HIF-1
have been identified. Moreover, both the expression of HIF-
1 and its transcription activity are tightly controlled by cel-
lular oxygen tension. Recent progress in the study of its regu-
lation mechanism gives us clues to the manner in which HIF-
1 is regulated by oxygen. In addition to HIF-1-mediated
adaptation to hypoxia, HIF-1 also contributes to other cel-
lular processes that occur under normoxic conditions, such
as the development of normal tissues or tumors, the deter-
mination of cell death or survival, immune responses, and the
adaptation to mechanical stresses. In these cases, the regula-
tion of HIF-1 is not dependent on oxygen tension, but medi-
ated by various stimuli. Finally, understanding the roles and
regulation mechanisms of HIF-1 will open a new era in the
development of therapeutic strategies against a variety of
pathologic conditions, such as ischemic/hypoxic injuries, tu-
mor growth, wound healing, and cardiovascular remodeling. 
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